ExlService Holdings, Inc. 8-K

What Happened

• ExlService Holdings, Inc. (EXLS) disclosed on June 24, 2026 (Purchase Agreement dated June 22, 2026) that its indirect wholly owned subsidiary Clairvoyant AI, Inc. agreed to buy all issued and outstanding equity of iMerit Inc. from the current owners.
• The deal calls for $170 million in upfront cash consideration (subject to customary adjustments for indebtedness, cash, working capital, etc.) and up to $140 million in additional cash incentives and earnouts payable over two years if specified milestones are met. A portion of the purchase price will be held in escrow for working capital and indemnifiable matters.
• The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions (including expiration/termination of applicable antitrust waiting periods). EXL expects to fund the purchase with available cash and borrowings from its credit facility. Ancillary agreements (escrow, employment offers, restrictive covenants) are contemplated at closing.

Key Details

• Purchase Agreement date: June 22, 2026; 8-K filed June 24, 2026.
• Upfront cash consideration: $170 million (adjustable); additional contingent payments: up to $140 million over two years.
• Expected close: Q3 2026, subject to customary closing conditions and antitrust waiting periods.
• Funding: available cash on hand and borrowings under EXL’s credit facility; portion of consideration to be held in escrow.

Why It Matters

• This is a material acquisition transaction for EXL that involves significant upfront cash and potential earnouts, affecting liquidity and near-term financing needs (EXL plans to use cash on hand and its credit facility).
• Closing is not guaranteed—subject to customary conditions and antitrust clearance—so timing and ultimate cost depend on adjustments, milestone achievement for earnouts, and regulatory outcomes.
• Investors should note the filing contains forward-looking statements and lists integration, milestone achievement, and regulatory risk as factors that could affect anticipated results.